[1] Malloy M W, McGrath K E, Morrell C N. Platelet heterogeneity: variety makes immune and vascular function better [J]. Blood, 2025, 146 (24): 2882-2888.
[2] Mo A, Wood E, McQuilten Z. Platelet transfusion [J]. Current Opinion in Hematology, 2025, 32 (1): 14-21.
[3] Jacobs J W, Raza S, Woo J S. Managing blood product shortages: unprecedented challenges require novel solutions [J]. Transfusion, 2024, 64 (3): 565-566.
[4] Li J J, Liu J, Li Y E, et al. Differentiation route determines the functional outputs of adult megakaryopoiesis [J]. Immunity, 2024, 57 (3): 478-494.e6.
[5] Stone A P, Nascimento T F, Barrachina M N. The bone marrow niche from the inside out: how megakaryocytes are shaped by and shape hematopoiesis [J]. Blood, 2022, 139 (4): 483-491.
[6] Foster H R, Colzani M, Bouet G, et al. Production of platelets in vitro in functionalized 3-dimensional scaffolds mimicking the bone marrow niche [J]. Haematologica, 2025, 110 (10): 2451-2462.
[7] Nakamura S, Takayama N, Hirata S, et al. Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells [J]. Cell Stem Cell, 2014, 14 (4): 535-548.
[8] Sugimoto N, Eto K. Generation and manipulation of human iPSC-derived platelets [J]. Cellular and Molecular Life Sciences, 2021, 78 (7): 3385-3401.
[9] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors [J]. Cell, 2006, 126 (4): 663-676.
[10] Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors [J]. Cell, 2007, 131 (5): 861-872.
[11] Dhaiban S, Chandran S, Noshi M, et al. Clinical translation of human iPSC technologies: advances, safety concerns, and future directions [J]. Frontiers in Cell and Developmental Biology, 2025, 13: 1627149.
[12] Peng F Q, Wang Y L, Cheng L, et al. Chemical reprogramming of human blood cells to pluripotent stem cells [J]. Cell Stem Cell, 2025, 32 (8): 1192-1199.e11.
[13] Matiukhova M, Ryapolova A, Andriianov V, et al. A comprehensive analysis of induced pluripotent stem cell (iPSC) production and applications [J]. Frontiers in Cell and Developmental Biology, 2025, 13: 1593207.
[14] Cerneckis J, Cai H X, Shi Y H. Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications [J]. Signal Transduction and Targeted Therapy, 2024, 9: 112.
[15] 周泽林，刘青青，张锋，等. CRISPR 基因编辑技术在 iPSC 中的研究与应用进展 [J]. 中国生物工程杂志，2025, 45 (9): 50-62. ZHOU Z L, LIU Q Q, ZHANG F, et al. Research progress and application of CRISPR gene editing in iPSCs [J]. China Biotechnology, 2025, 45 (9): 50-62.
[16] Furniss J A, Tarassova N, Poole A W. Platelet generation in vivo and in vitro [J]. Blood, 2024, 144 (22): 2283-2294.
[17] Gaur M, Kamata T, Wang S, et al. Megakaryocytes derived from human embryonic stem cells: a genetically tractable system to study megakaryocytopoiesis and integrin function [J]. Journal of Thrombosis and Haemostasis, 2006, 4 (2): 436-442.
[18] Takayama N, Nishikii H, Usui J, et al. Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors [J]. Blood, 2008, 111 (11): 5298-5306.
[19] Takayama N, Eto K, Nakauchi H, et al. Generation of blood cells from human iPS cells in vitro through the hematopoietic progenitors concentrated within the unique structures, ips-sac [J]. Blood, 2008, 112 (11): 1992.
[20] Mazurek M, Młynarski W, Grzela D P. In vitro derivation of megakaryocytes and platelets from induced pluripotent stem cells: developmental foundations and translational perspectives [J]. Frontiers in Immunology, 2025, 16: 1720048.
[21] De Roo J J D, Staal F J T. Cell signaling pathway reporters in adult hematopoietic stem cells [J]. Cells, 2020, 9 (10): 2264.
[22] Liu G, Hou Y X, Jin X, et al. PI3K/HSCB axis facilitates FOG1 nuclear translocation to promote erythropoiesis and megakaryopoiesis [J]. eLife, 2024, 13: RP95815.
[23] Li Y, Jin C, Bai H, et al. Human NOTCH4 is a key target of RUNX1 in megakaryocytic differentiation [J]. Blood, 2018, 131 (2): 191-201.
[24] Zhang L, Wang H, Liu C, et al. MSX2 initiates and accelerates mesenchymal stem/stromal cell specification of hPSCs by regulating TWIST1 and PRAME [J]. Stem Cell Reports, 2018, 11 (2): 497-513.
[25] Behrens K, Kauppi M, Viney E M, et al. Differential in vivo roles of Mpl cytoplasmic tyrosine residues in murine hematopoiesis and myeloproliferative disease [J]. Leukemia, 2024, 38 (6): 1342-1352.
[26] Kaushansky K. Thrombopoietin, the primary regulator of platelet production: from mythos to logos, a thirty-year journey [J]. Biomolecules, 2024, 14 (4): 489.
[27] 中华医学会血液学分会红细胞疾病学组，韩冰，张连生，等。促血小板生成药物治疗再生障碍性贫血专家共识 [J]. 中国实用内科杂志，2025, 45 (1): 32-47. Red Blood Cell Disease Group of Hematology Branch of Chinese Medical Association, HAN B, ZHANG L S, et al. Expert consensus on thrombopoietic agents for aplastic anemia [J]. Chinese Journal of Practical Internal Medicine, 2025, 45 (1): 32-47.
[28] Singh V K, Kumar N, Kalsan M, et al. A novel peptide thrombopoietin mimetic designing and optimization using computational approach [J]. Frontiers in Bioengineering and Biotechnology, 2016, 4: 69.
[29] Kim J E, Lee Y, Kim Y, et al. Chemically defined, efficient megakaryocyte production from human pluripotent stem cells [J]. Cells, 2025, 14 (22): 1835.
[30] Jarocha D, Vo K K, Lyde R B, et al. Enhancing functional platelet release in vivo from in vitro-grown megakaryocytes using small molecule inhibitors [J]. Blood Advances, 2018, 2 (6): 597-606.
[31] Avanzi M P, Goldberg F, Davila J, et al. Rhokinase inhibition drives megakaryocyte polyploidization and proplatelet formation through MYC and NFE2 downregulation [J]. British Journal of Haematology, 2014, 164 (6): 867-876.
[32] Krisch L, Brachtl G, Hochmann S, et al. Improving human induced pluripotent stem cell-derived megakaryocyte differentiation and platelet production [J]. International Journal of Molecular Sciences, 2021, 22 (15): 8224.
[33] Liu H C, Wang L N, Liu J Q, et al. Efficient generation of megakaryocyte progenitors and platelets from HSPCs via JAK2/STAT3 signaling [J]. Advanced Science, 2025, 12 (23): 2500612.
[34] Takayama N, Nishimura S, Nakamura S, et al. Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells [J]. Journal of Experimental Medicine, 2010, 207 (13): 2817-2830.
[35] Nakamura S, Sugimoto N, Eto K. Ex vivo generation of platelet products from human iPS cells [J]. Inflammation and Regeneration, 2020, 40 (1): 30.
[36] Dhanasekaran R, Deutzmann A, Mahauad-Fernandez W D, et al. The MYC oncogene: the grand orchestrator of cancer growth and immune evasion [J]. Nature Reviews Clinical Oncology, 2022, 19 (1): 23-36.
[37] Sone M, Nakamura S, Umeda S, et al. Silencing of p53 and CDKN1A establishes sustainable immortalized megakaryocyte progenitor cells from human iPSCs [J]. Stem Cell Reports, 2021, 16 (12): 2861-2870.
[38] Chen S J, Hashimoto K, Fujio K, et al. A let-7 microRNA–RALB axis links the immune properties of iPSC-derived megakaryocytes with platelet producibility [J]. Nature Communications, 2024, 15 (1): 2588.
[39] Moreau T, Evans A L, Vasquez L, et al. Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming [J]. Nature Communications, 2016, 7: 11208.
[40] Dalby A, Ballester-Beltrán J, Lincetto C, et al. Transcription factor levels after forward programming of human pluripotent stem cells with GATA1, FLI1, and TAL1 determine megakaryocyte versus erythroid cell fate decision [J]. Stem Cell Reports, 2018, 11 (6): 1462-1478.
[41] Evans A L, Dalby A, Foster H R, et al. Transfer to the clinic: refining forward programming of hPSCs to megakaryocytes for platelet production in bioreactors [J]. Blood Advances, 2021, 5 (7): 1977-1990.
[42] Wang H T, He J, Xu C L, et al. Decoding human megakaryocyte development [J]. Cell Stem Cell, 2021, 28 (3): 535-549.e8.
[43] Liu C C, Wu D, Xia M J, et al. Characterization of cellular heterogeneity and an immune subpopulation of human megakaryocytes [J]. Advanced Science, 2021, 8 (15): 2100921.
[44] Luis T C, Barkas N, Carrelha J, et al. Perivascular niche cells sense thrombocytopenia and activate hematopoietic stem cells in an IL-1 dependent manner [J]. Nature Communications, 2023, 14 (1): 6062.
[45] Yue W, Yang Y, Miao Y, et al. Optimizing the method for differentiation of functional platelets from human induced pluripotent stem cells [J]. Stem Cell Reviews and Reports, 2026, 22 (3): 1325-1340.
[46] Junt T, Schulze H, Chen Z, et al. Dynamic visualization of thrombopoiesis within bone marrow [J]. Science, 2007, 317 (5845): 1767-1770.
[47] Guinard I, Brassard-Jollive N, Ruch L, et al. Mechanical confinement prevents ectopic platelet release [J]. Proceedings of the National Academy of Sciences of the United States of America, 2024, 121 (38): e2407829121.
[48] Di Buduo C A, Wray L S, Tozzi L, et al. Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies [J]. Blood, 2015, 125 (14): 2254-2264.
[49] Nwokoye P N, Abilez O J. Bioengineering methods for vascularizing organoids [J]. Cell Reports Methods, 2024, 4 (6): 100779.
[50] Ito Y, Nakamura S, Sugimoto N, et al. Turbulence activates platelet biogenesis to enable clinical scale ex vivo production [J]. Cell, 2018, 174 (3): 636-648.e18.
[51] Dunois-Lardé C, Capron C, Fichelson S, et al. Exposure of human megakaryocytes to high shear rates accelerates platelet production [J]. Blood, 2009, 114 (9): 1875-1883.
[52] Yang Y Q, Liu C C, Lei X H, et al. Integrated biophysical and biochemical signals augment megakaryopoiesis and thrombopoiesis in a three-dimensional rotary culture system [J]. Stem Cells Translational Medicine, 2016, 5 (2): 175-185.
[53] 姚舜，杨咏琪，刘翠翠，等。血小板临床转化研究进展 [J]. 中国细胞生物学学报，2026, 48 (1): 116-128. YAO S, YANG Y Q, LIU C C, et al. Research progress on clinical translation of platelets [J]. Chinese Journal of Cell Biology, 2026, 48 (1): 116-128.
[54] Garzon Dasgupta A K, Pongérard A, Mallo L, et al. Uniform impact on individual megakaryocytes is essential for efficient in vitro platelet production [J]. Scientific Reports, 2025, 15 (1): 1809.
[55] Lawrence M, Evans A, Moreau T, et al. Process analysis of pluripotent stem cell differentiation to megakaryocytes to make platelets applying European GMP [J]. npj Regenerative Medicine, 2021, 6 (1): 27.
[56] 中华医学会血液学分会。血小板无效输注诊断和治疗中国专家共识（2022 年版）[J]. 中华血液学杂志，2022, 43 (11): 897-902. Hematology Branch of Chinese Medical Association. Chinese expert consensus on diagnosis and management of platelet transfusion refractoriness (2022 edition)[J]. Chinese Journal of Hematology, 2022, 43 (11): 897-902.
[57] Couvidou A, Rojas-Jiménez G, Dupuis A, et al. Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects [J]. Frontiers in Immunology, 2023, 14: 1125367.
[58] Cabral L J B, Lopes D P, dos Santos Martins Filho E, et al. Anti-HLA antibody formation increases the chances of platelet refractoriness in platelet-transfused patients: a systematic review with meta-analysis [J]. Hematology, Transfusion and Cell Therapy, 2025, 47 (2): 103821.
[59] Sugimoto N, Nakamura S, Shimizu S, et al. Production and nonclinical evaluation of an autologous iPSC-derived platelet product for the iPLAT1 clinical trial [J]. Blood Advances, 2022, 6 (23): 6056-6069.
[60] Sugimoto N, Kanda J, Nakamura S, et al. iPLAT1: the first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study [J]. Blood, 2022, 140 (22): 2398-2402.
[61] Figueiredo C, Blasczyk R. Generation of HLA universal megakaryocytes and platelets by genetic engineering [J]. Frontiers in Immunology, 2021, 12: 768458.
[62] Börger A K, Eicke D, Wolf C, et al. Generation of HLA-universal iPSC-derived megakaryocytes and platelets for survival under refractoriness conditions [J]. Molecular Medicine, 2016, 22 (1): 274-285.
[63] Giannotti L, Di Chiara Stanca B, Spedicato F, et al. Progress in regenerative medicine: exploring autologous platelet concentrates and their clinical applications [J]. Genes, 2023, 14 (9): 1669.
[64] Collins T, Alexander D, Barkatali B. Platelet-rich plasma: a narrative review [J]. EFORTOpen Reviews, 2021, 6 (4): 225-235.
[65] Lopes-Silva R, Santos M, Sequeira M L, et al. Platelet-rich plasma effectiveness in treating androgenetic alopecia: a comprehensive evaluation [J]. Cureus, 2025, 17 (1): e77371.
[66] Xu H, Huang K, Tao X. Efficacy and safety of platelet-rich plasma versus conventional care in diabetic foot ulcers: a meta-analysis of randomized controlled trials [J]. Acta Diabetologica, 2025, 62 (10): 1585-1596.
[67] Huang S, Li Q, Li X, et al. Recent research progress of wound healing biomaterials containing platelet-rich plasma [J]. International Journal of Nanomedicine, 2025, 20: 3961-3976.
[68] Qu W C, Wang Z, Hunt C, et al. The effectiveness and safety of platelet-rich plasma for chronic wounds: a systematic review and meta-analysis [J]. Mayo Clinic Proceedings, 2021, 96 (9): 2407-2417.
[69] Xie L, Gan F, Hu Y, et al. From blood to therapy: the revolutionary application of platelets in cancer-targeted drug delivery [J]. Journal of Functional Biomaterials, 2025, 16 (1): 15.
[70] Yao C, Wang C. Platelet-derived extracellular vesicles for drug delivery [J]. Biomaterials Science, 2023, 11 (17): 5758-5768.
[71] Zhu Y L, Xu L L, Kang Y, et al. Platelet-derived drug delivery systems: pioneering treatment for cancer, cardiovascular diseases, infectious diseases, and beyond [J]. Biomaterials, 2024, 306: 122478.
[72] Zhao Z J, Yang Y X, Sheng T, et al. Platelet-drug conjugates engineered via one-step fusion approach for metastatic and postoperative cancer treatment [J]. Angewandte Chemie International Edition, 2024, 63 (37): e202403541.
[73] Bahmani B, Gong H, Luk B T, et al. Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors [J]. Nature Communications, 2021, 12 (1): 1999.
[74] Song Y A, Huang Z Y, Liu X, et al. Platelet membrane-coated nanoparticle-mediated targeting delivery of rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein E-deficient (ApoE-/-) mice [J]. Nanomedicine: Nanotechnology, Biology and Medicine, 2019, 15 (1): 13-24.
[75] Song B, Na Y G, Kim B J, et al. Platelet membrane-coated poly (lactic-co-glycolic acid) nanoparticles as a targeting drug delivery system for multidrug-resistant breast cancer [J]. International Journal of Nanomedicine, 2025, 20: 8529-8545.
[76] Kubaev A, Faez Sead F, Pirouzbakht M, et al. Platelet-derived extracellular vesicles: emerging players in hemostasis and thrombosis [J]. Journal of Liposome Research, 2025, 35 (3): 334-344.
[77] Ma Q L, Fan Q, Han X, et al. Platelet-derived extracellular vesicles to target plaque inflammation for effective anti-atherosclerotic therapy [J]. Journal of Controlled Release, 2021, 329: 445-453.
)
